Highlights of weekly biotech stock moves

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $2.78 to $66.15 on Friday after FDA granted accelerated approval to Soliris eculizumab to treat atypical hemolytic uremic syndrome, a rare and chronic blood disease that can lead to renal failure. Separately, EMA's CHMP issued a positive opinion backing approval of the drug for the indication. Soliris is already approved in the EU, Japan and the U.S. for paroxysmal nocturnal hemoglobinuria. Alexion gained $4.08 on the week.

BTG plc (LSE:BGC) was off 21.10p to 254.90p last week after FDA accepted and granted Priority Review to a BLA for Voraxaze glucarpidase to reduce methotrexate levels due to impaired renal function. The PDUFA date is Jan. 17, 2012...